 | |
| Company type | Subsidiary |
|---|---|
| NYSE: BXLT | |
| Industry | Biotechnology |
| Founded | 2015 (Spun off from Baxter International) |
| Fate | Acquired by Shire |
| Headquarters | United States  |
Key people | Ludwig N. Hantson (president and CEO) |
| Products | Hematology, Immunology, Pulmonology |
Number of employees | 16,000[1] |
| Parent | Takeda Pharmaceutical Company |
| Website | www |
Baxalta (Bax from the name of its former parent company; alta a Latin adjective meaning 'high' or 'profound'[2]) is a biopharmaceutical company founded on 1 July 2015 after its parent company, Baxter International, spun off biopharmaceutical division.[1] The company began its operation with a revenue of $6 billion,[3] and is now a subsidiary of Takeda Pharmaceutical Company.
- ^ a b Ben Reynolds. "Baxalta: A Rare Undervalued Biopharmaceutical Company". cnafinance.com. Archived from the original on 2015-07-24. Retrieved 2015-07-23.
- ^ Timmins, Peter (January 2015). "Industry Update". Therapeutic Delivery. 6 (1): 9–15. doi:10.4155/tde.14.103.
- ^ "Baxalta: Baxter's newly named biopharma spinout has had its ups and downs". FierceBiotech.